Tricyclic Diterpenoids Selectively Suppress Androgen Receptor-Positive Prostate Cancer Cells
Open Access
Abstract
Androgen receptor (AR) is a viable therapeutic target for lethal castration-resistant prostate cancer (CRPC), because the continued progression of CRPC is mainly driven by the reactivation of AR transcriptional activity. The current FDA-approved AR antagonists binding to ligand binding domain (LBD) become ineffective in CRPC with AR gene amplification, LBD mutation, and the evolution of LBD-truncated AR splice variants. Encouraged by the fact that tricyclic aromatic diterpenoid QW07 has recently been established as a potential N-terminal AR antagonist, this study aims to explore the structure–activity relationship of tricyclic diterpenoids and their potential to suppress AR-positive cell proliferation. Dehydroabietylamine, abietic acid, dehydroabietic acid, and their derivatives were selected, since they have a similar core structure as QW07. Twenty diterpenoids were prepared for the evaluation of their antiproliferative potency on AR-positive prostate cancer cell models (LNCaP and 22Rv1) using AR-null cell models (PC-3 and DU145) as comparisons. Our data indicated that six tricyclic diterpenoids possess greater potency than enzalutamide (FDA-approved AR antagonist) towards LNCaP and 22Rv1 AR-positive cells, and four diterpenoids are more potent than enzalutamide against 22Rv1 AR-positive cells. The optimal derivative possesses greater potency (IC50 = 0.27 µM) and selectivity than QW07 towards AR-positive 22Rv1 cells.Keywords
Funding Information
- California State University (G12MD007595, R25GM131956, HRD-1826490, T32GM137948)
- National Institutes of Health (G12MD007595, R25GM131956, HRD-1826490, T32GM137948)
- NIH RISE Program (G12MD007595, R25GM131956, HRD-1826490, T32GM137948)
- CSU-LSAMP program (G12MD007595, R25GM131956, HRD-1826490, T32GM137948)
- CSU-Fresno Bridge to Doctorate Program (G12MD007595, R25GM131956, HRD-1826490, T32GM137948)
This publication has 23 references indexed in Scilit:
- Carnosol: A Phenolic Diterpene With Cancer Chemopreventive PotentialJournal of Cancer Prevention, 2014
- Androgen receptor: structure, role in prostate cancer and drug discoveryActa Pharmacologica Sinica, 2014
- Carnosic acid modulates Akt/IKK/NF-κB signaling by PP2A and induces intrinsic and extrinsic pathway mediated apoptosis in human prostate carcinoma PC-3 cellsApoptosis, 2012
- Synthesis and biological evaluation of dehydroabietic acid derivativesEuropean Journal of Medicinal Chemistry, 2010
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate CancerScience, 2009
- Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletionNature Reviews Endocrinology, 2009
- A Novel Diterpene Suppresses CWR22Rv1 Tumor Growth In vivo through Antiproliferation and ProapoptosisCancer Research, 2008
- Ferruginol suppresses survival signaling pathways in androgen-independent human prostate cancer cellsBiochimie, 2008
- Androgen Receptor in Prostate CancerEndocrine Reviews, 2004
- A history of prostate cancer treatmentNature Reviews Cancer, 2002